🧬 Pharma Marketing, Compounding, and the GLP-1 Gray Zone | Sabrina Johnson (2/4)

episode

The Biotech Startups Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

The Chris Wolfe Podcast: The Power of Quality Supplements 48 min · 14 Sep 2026 · EyeCode Media

1208: TM Europe win the '26 Solheim Cup 1h 49m · 13 Sep 2026 · No Laying Up - Golf Podcast

MORNING TEA: Harry & Meghan's Brutal SNL Roast, Lady Gaga's Baby News & Dakota Johnson's New Man 8 min · 13 Sep 2026 · The Spill

"I don't think they have enough match winners."| First Thoughts - Brisbane vs Adelaide (14.09.26) 15 min · 13 Sep 2026 · SEN Breakfast

Full Show Podcast: 14 September 2026 1h 28m · 13 Sep 2026 · The Mike Hosking Breakfast

Report any issue

Source

Recorded21 May 2026

Publisherfeeds.fame.so ↗

Handlerec:18526589

Show notes

In this episode of The Biotech Startups Podcast, Jon Chee continues his conversation with Sabrina Johnson, President and CEO of DARÉ Bioscience. Sabrina traces her path from a name-tag encounter that led her to Advanced Tissue Sciences to joining Cypress Bioscience in 1998. She unpacks pharmaceutical marketing regulation, the medical-regulatory-legal review process, and the gray zone of compounded GLP-1s — including DARÉ's decision to make its sildenafil cream available via 503B rather than leave women without a validated option.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in